ArticleEMBO molecular medicine2021
Gut microbiota-CRAMP axis shapes intestinal barrier function and immune responses in dietary gluten-induced enteropathy.
Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Celiac disease and the gut microbiota: bibliometric mapping of research hotspots and immune-mechanistic trends.Frontiers in immunology · 2026Pooled it
- Immunomodulatory effects of cathelicidin in the gut-brain axis: A novel link between mucosal immunity and neuroinflammation.Experimental physiology · 2026Review
- Small molecule inhibitor targets OmpV to treat pandemic Vibrio cholerae infection.Nature communications · 2025Article
- Interleukin 15 and autoimmune disorders: pathophysiology, therapeutic potential, and clinical implications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Bifidobacterium longum Ameliorates Intestinal Inflammation and Metabolic Biomarkers in Mice Fed a High-Fat Diet with Gliadin by Indoleacrylic Acid.Probiotics and antimicrobial proteins · 2025Article
- Lactiplantibacillus plantarum Moderating Effect on Autoimmune Celiac Disease Triggers.Probiotics and antimicrobial proteins · 2025Review
- Effects of dietary gluten on body weight and gut microbiota in BALB-C mice using 16 S rRNA-Based analysis.Scientific reports · 2025Article
- PasteurizedFrontiers in microbiology · 2025Article
- Zinc bioaccessibility of foodstuffs afterFood & nutrition research · 2025Article
- Monocyte-driven inflamm-aging reduces intestinal barrier function in females.Immunity & ageing : I & A · 2024Article
- Bacteria: Potential Make-or-Break Determinants of Celiac Disease.International journal of molecular sciences · 2024Review
- [Analysis of gut target microbiota and species difference in patients with obstructive sleep apnea based on 16S rRNA sequencing].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Regulation of chlamydial spreading from the small intestine to the large intestine by IL-22-producing CD4Infection and immunity · 2024Article
- Alterations in metabolome and microbiome: new clues on cathelicidin-related antimicrobial peptide alleviates acute ulcerative colitis.Frontiers in microbiology · 2024Article
- Gut microbiota controls the development of chronic pancreatitis: A critical role of short-chain fatty acids-producing Gram-positive bacteria.Acta pharmaceutica Sinica. B · 2023Article
- A Bioresponsive Genetically Encoded Antimicrobial Crystal for the Oral Treatment of Helicobacter Pylori Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Diet Quality, Microbial Lignan Metabolites, and Cardiometabolic Health among US Adults.Nutrients · 2023Article
- The effects and significance of gut microbiota and its metabolites on the regulation of osteoarthritis: Close coordination of gut-bone axis.Frontiers in nutrition · 2022Review
- Gut microbiota-CRAMP axis shapes intestinal barrier function and immune responses in dietary gluten-induced enteropathy.EMBO molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the gut, cathelicidin-related antimicrobial peptide (CRAMP) has been largely described for its anti-infective activities. With an increasing recognition of its immune regulatory effects in extra-intestinal diseases, the role of CRAMP in gluten-induced small intestinal enteropathy celiac disease remains unknown. This study aimed to investigate the unexplored role of CRAMP in celiac disease. By applying a mouse model of gluten-induced enteropathy (GIE) recapitulating small intestinal enteropathy of celiac disease, we observed defective CRAMP production in duodenal epithelium during GIE. CRAMP-deficient mice were susceptible to the development of GIE. Exogenous CRAMP corrected gliadin-triggered epithelial dysfunction and promoted regulatory immune responses at the intestinal mucosa. Additionally, GIE-associated gut dysbiosis with enriched Pseudomonas aeruginosa and production of the protease LasB contributed to defective intestinal CRAMP production. These results highlight microbiota-CRAMP axis in the modulation of barrier function and immune responses in GIE. Hence, modulating CRAMP may represent a therapeutic strategy for celiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.